The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Platinum‐based anticancer agents: Innovative design strategies and biological perspectives
Abstract
The impact of cisplatin on cancer chemotherapy cannot be denied. Over the past 20 years, much effort has been dedicated to discover new platinum‐based anticancer agents that are superior to cisplatin or its analogue, carboplatin. Most structural modifications are based on changing one or both of the ligand types coordinated to platinum. Altering the leaving group can influence tissue and intracellular distribution of the drug, whereas the carrier ligand usually determines the structure of adducts formed with DNA. DNA–Pt adducts produced by cisplatin and many of its classical analogues are almost identical, and would explain their similar patterns of tumor sensitivity and susceptibility to resistance. Recently some highly innovative design strategies have emerged, aimed at overcoming platinum resistance and/or to introduce novel mechanisms of antitumor action. Platinum compounds bearing the 1,2‐diaminocyclohexane carrier ligand; and those of multinuclear Pt complexes giving rise to radically different DNA–Pt adducts, have resulted in novel anticancer agents capable of circumventing cisplatin resistance. Other strategies have focused on integrating biologically active ligands with platinum moieties intended to selectively localizing the anticancer properties. With the rapid advance in molecular biology, combined with innovation, it is possible new Pt‐based anticancer agents will materialize in the near future. © 2003 Wiley Periodicals, Inc. Med Res Rev, 23, No. 5, 633–655, 2003
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Death: The Significance of Apoptosis
Wyllie, A. H., Kerr, J. F. R., & Currie, A. R. (1980) · International Review of Cytology · doi:10.1016/s0074-7696(08)62312-8 · Cited by 7,162
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Current Status of Platinum-Based Antitumor Drugs
Wong, E., & Giandomenico, C. M. (1999) · Chemical Reviews · doi:10.1021/cr980420v · Cited by 1,800
EINHORN, L. H., & DONOHUE, J. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-3-293 · Cited by 1,545
Taxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
LOEHRER, P. J., & EINHORN, L. H. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-5-704 · Cited by 947
Structural aspects of platinum anticancer drug interactions with DNA
Sherman, S. E., & Lippard, S. J. (1987) · Chemical Reviews · doi:10.1021/cr00081a013 · Cited by 930
Apoptosis induced by anticancer drugs
Hickman, J. A. (1992) · Cancer and Metastasis Review · doi:10.1007/bf00048059 · Cited by 863
Lebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
Chu, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42175-2 · Cited by 651
Oxaliplatin: A review of preclinical and clinical studies
Raymond, E., Chaney, S. G., Taamma, A., & Cvitkovic, E. (1998) · Annals of Oncology · doi:10.1023/a:1008213732429 · Cited by 643
Serine/threonine protein phosphatases
Wera, S., & Hemmings, B. A. (1995) · Biochemical Journal · doi:10.1042/bj3110017 · Cited by 635
Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., & Fojo, T. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)81490-6 · Cited by 615
The role of DNA mismatch repair in platinum drug resistance.
Fink, D. A., Nebel, S., Aebi, S. P., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., & Howell, S. B. (1996) · PubMed · Cited by 597
Carrico, C. K. (1983) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(83)90505-9 · Cited by 588
Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond, É., Faivre, S. J., WOYNAROWSKI, J. M., & Chaney, S. G. (1998) · PubMed · Cited by 520
Sontag, E., Fedorov, S., Kamibayashi, C., Robbins, D., Cobb, M., & Mumby, M. (1993) · Cell · doi:10.1016/0092-8674(93)90533-v · Cited by 510
Knox, R. J., Friedlos, F., Lydall, D. A., & Roberts, J. J. (1986) · PubMed · Cited by 498
Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance.
Searle, J. W., Kerr, J. F. R., & Bishop, C. (1982) · PubMed · Cited by 493
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II
Calvert, A. H., Harland, S. J., Newell, D. R., Siddik, Z. H., Jones, A. C., McElwain, T. J., Raju, S., Wiltshaw, E., Smith, I. E., Baker, J. M., et al. (1982) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00257742 · Cited by 484
An improved procedure for identifying and quantitating protein phosphatases in mammalian tissues
Cohen, P., Klumpp, S., & Schelling, D. L. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)80803-8 · Cited by 471
Cellular and molecular pharmacology of oxaliplatin.
Raymond, É., Faivre, S. J., Chaney, S. G., WOYNAROWSKI, J. M., & Cvitkovic, E. (2002) · PubMed · Cited by 463
Medical uses of mylabris in ancient China and recent studies
Wang, G.-S. (1989) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(89)90062-7 · Cited by 421
Rosenberg, B., Van Camp, L., Grimley, E. B., & Thomson, A. J. (1967) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)96186-7 · Cited by 420
New Cisplatin Analogues in Development: A Review
Weiss, R. B., & Christian, M. C. (1993) · Drugs · doi:10.2165/00003495-199346030-00003 · Cited by 404
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
Reed, E. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90056-1 · Cited by 397
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.
Andrews, P. A., & Howell, S. B. (1990) · PubMed · Cited by 397
Reaction Mechanism of Human DNA Repair Excision Nuclease
Mu, D., Hsu, D. S., & Sancar, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.8285 · Cited by 374
Platinum coordination complexes in cancer chemotherapy
Rosenberg, B. (1973) · Die Naturwissenschaften · doi:10.1007/bf00623551 · Cited by 374
Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy
(1991) · Springer eBooks · doi:10.1007/978-1-4899-0738-7 · Cited by 374
Clinical Perspectives on Platinum Resistance
Giaccone, G. (2000) · Drugs · doi:10.2165/00003495-200059004-00002 · Cited by 364
Huang, J. C., Zamble, D. B., Reardon, J. T., Lippard, S. J., & Sancar, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10394 · Cited by 347
High-Dose Cisplatin in Hypertonic Saline
OZOLS, R. F., CORDEN, B. J., JACOB, J., WESLEY, M. N., OSTCHEGA, Y., & YOUNG, R. C. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-1-19 · Cited by 333
Sorenson, C. M., & Eastman, A. R. (1988) · PubMed · Cited by 306
Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C., Hamilton, T. C., & Chaney, S. G. (1998) · PubMed · Cited by 294
Preclinical Perspectives on Platinum Resistance
Kelland, L. R. (2000) · Drugs · doi:10.2165/00003495-200059004-00001 · Cited by 280
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
Fink, D. A., Zheng, H., Nebel, S., Norris, P. S., Aebi, S. P., Lin, T., Nehmé, A., Christen, R. D., Haas, M., MacLeod, C. L., et al. (1997) · PubMed · Cited by 277
Mistry, P., Kelland, L., Abel, G., Sidhar, S., & Harrap, K. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.279 · Cited by 261
Preclinical studies identifying carboplatin as a viable cisplatin alternative
Harrap, K. R. (1985) · Cancer Treatment Reviews · doi:10.1016/0305-7372(85)90015-5 · Cited by 259
Cantharidin-binding protein: identification as protein phosphatase 2A.
Li, Y. M., & Casida, J. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.11867 · Cited by 256
Bcl-2 and Bcl-XL Can Differentially Block Chemotherapy-Induced Cell Death
Simonian, P. L., Grillot, D. A. M., & Nuñez, G. (1997) · Blood · doi:10.1182/blood.v90.3.1208 · Cited by 242
New platinum complexes with anti-tumour activity
Connors, T. A., Jones, M., Ross, W. C. J., Braddock, P. D., Khokhar, A. R., & Tobe, M. L. (1972) · Chemico-Biological Interactions · doi:10.1016/0009-2797(72)90078-6 · Cited by 240
Kèlland, L. R., Abel, G., McKeage, M. J., Jones, M., Goddard, P. M., Valenti, M., Murrer, B. A., & Harrap, K. R. (1993) · PubMed · Cited by 224
The 55 kd regulatory subunit of Drosophila protein phosphatase 2A is required for anaphase
Mayer-Jaekel, R. E., Ohkura, H., Gomes, R., Sunkel, C. E., Baumgartner, S., Hemmings, B. A., & Glover, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90080-a · Cited by 216
Anthracycline Antibiotics in Cancer Therapy: Focus on Drug Resistance
Booser, D. J., & Hortobagyi, G. N. (1994) · Drugs · doi:10.2165/00003495-199447020-00002 · Cited by 214
Versantvoort, C., Broxterman, H., Bagrij, T., Scheper, R., & Twentyman, P. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.281 · Cited by 207
Type 2A protein phosphatase, the complex regulator of numerous signaling pathways
Zolnierowicz, S. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00424-x · Cited by 200
Holford, J., Sharp, S., Murrer, B., Abrams, M., & Kelland, L. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.59 · Cited by 196
Clarke, P. R., Hoffmann, I., Draetta, G., & Karsenti, E. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.4.397 · Cited by 190
Tashiro, T., Kawada, Y., Sakurai, Y., & Kidani, Y. (1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90004-8 · Cited by 171
Effect of Glutathione on DNA Repair in Cisplatin-Resistant Human Ovarian Cancer Cell Lines
Lai, G.-M., Ozols, R. F., Young, R. C., & Hamilton, T. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.7.535 · Cited by 167
Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins
Yamada, M. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.3.491 · Cited by 161
Treiber, D. K., Zhai, X., Jantzen, H., & Essigmann, J. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5672 · Cited by 151
Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality
Page, J. D., Husain, I., Sancar, A., & Chaney, S. G. (1990) · Biochemistry · doi:10.1021/bi00456a026 · Cited by 139
Wolf, C. R., Hayward, I. P., Lawrie, S. S., BUCKTON, K. E., McIntyre, M. A., Adams, D. J., Lewis, A. D., Scott, A. R. R., & Smyth, J. F. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910390607 · Cited by 135
Reedijk, J., Fichtinger-Schepman, A. M. J., van Oosterom, A. T., & van de Putte, P. (1987) · Structure and bonding · doi:10.1007/3-540-17881-3_2 · Cited by 130
Hospers, G. A. P. (1989) · Lung Cancer · doi:10.1016/0169-5002(89)90120-7 · Cited by 129
Cisplatin-associated neurotoxicity: can it be prevented?
Alberts, D. S., & Noel, J. K. (1995) · Anti-Cancer Drugs · doi:10.1097/00001813-199506000-00003 · Cited by 126
Raynaud, F. I., Boxall, F. E., Goddard, P. M., Valenti, M. R., Jones, M. A., Murrer, B. A., Abrams, M., & Kèlland, L. R. (1997) · PubMed · Cited by 121
Complementary medicine: a review of immunomodulatory effects of Chinese herbal medicines
Borchers, A. T., Hackman, R., Keen, C. L., Stern, J., & Gershwin, M. (1997) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/66.6.1303 · Cited by 121
The Mechanism of Action of Cisplatin: From Adducts to Apoptosis
Eastman, A. R. (1999) · doi:10.1002/9783906390420.ch4 · Cited by 120
Mellish, K. J., Kèlland, L. R., & Harrap, K. R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.322 · Cited by 115
Farrell, N. P. (1993) · Cancer Investigation · doi:10.3109/07357909309011676 · Cited by 113
Farrell, N. P., Appleton, T. G., Qu, Y., Roberts, J. D., Fontes, A. P. S., Skov, K. A., Wu, P., & Zou, Y. (1995) · Biochemistry · doi:10.1021/bi00047a013 · Cited by 108
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
Bergan, R. C., Reed, E., Myers, C. E., Headlee, D. J., Brawley, O. W., Cho, H. K., Figg, W. D., Tompkins, A. C., Linehan, W. M., Köhler, D., et al. (1999) · PubMed · Cited by 108
Liu, X., Blazsek, I., Comisso, M., Gras, S. L., Marion, S., Quittet, P., Anjo, A., Wang, G.-S., & Misset, J. L. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00050-x · Cited by 104
O'Dwyer, P. J., Hamilton, T. C., Young, R. C., LaCreta, F. P., Carp, N. Z., Tew, K. D., Padavic, K., Comis, R. L., & Ozols, R. F. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.4.264 · Cited by 99
Cumulative renal tubular damage associated with cisplatin nephrotoxicity
Goren, M. P., Wright, R. K., & Horowitz, M. E. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00253068 · Cited by 94
Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines.
Henkels, K. M., & Turchi, J. J. (1997) · PubMed · Cited by 89
Teicher, B. A., Holden, S. A., Herman, T. S., Sotomayor, E. A., Khandekar, V. S., Rosbe, K. W., Brann, T. W., Korbut, T. T., & Frei, E. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910470214 · Cited by 87
Ariza, R. R., Keyse, S. M., Moggs, J. G., & Wood, R. D. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.3.433 · Cited by 86
Rationale for development of platinum analogs.
Jh, B., Kalaher, K., Dew, K., & Lokys, L. (1979) · PubMed · Cited by 81
Specificity of platinum–DNA adduct repair
Chaney, S. G., & Vaisman, A. (1999) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(99)00149-x · Cited by 69
Johnson, S. W., Shen, D.-W., Pastan, I. H., Gottesman, M. M., & Hamilton, T. C. (1996) · Experimental Cell Research · doi:10.1006/excr.1996.0211 · Cited by 69
Ovarian cancer: new clinical approaches
Ozols, R. F. (1991) · Cancer Treatment Reviews · doi:10.1016/0305-7372(91)90027-w · Cited by 67
Turchi, J. J., & Henkels, K. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13861 · Cited by 66
Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro
Yi, S., Wass, J., Vincent, P., & Iland, H. J. (1991) · Leukemia Research · doi:10.1016/0145-2126(91)90163-n · Cited by 64
Murray, V., Motyka, H., England, P. R., Wickham, G., Lee, H. H., Denny, W. A., & McFadyen, W. D. (1992) · Biochemistry · doi:10.1021/bi00162a020 · Cited by 64
Mechanisms of Resistance to Platinum Drugs
Eastman, A. R., Schulte, N. A., Sheibani, N., & Sorenson, C. M. (1988) · Springer eBooks · doi:10.1007/978-1-4613-1717-3_20 · Cited by 62
Intracellular glutathione and cytotoxicity of platinum complexes
Pendyala, L., Creaven, P. J., Perez, R. P., Zdanowicz, J., & Raghavan, D. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689042 · Cited by 45
Regulation of gene expression by serine/threonine protein phosphatases
Schönthal, A. H. (1995) · Seminars in Cancer Biology · doi:10.1006/scbi.1995.0031 · Cited by 39
Cantharidin poisoning associated with specific binding site in liver
Graziano, M. J., Waterhouse, A. L., & Casida, J. E. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)91607-x · Cited by 38
The role of protein phosphatase type-2A in the cell cycle: initiation of the G2/M transition
Lee, T. H. (1995) · Seminars in Cancer Biology · doi:10.1006/scbi.1995.0027 · Cited by 38
Alternative and Complementary Cancer Treatments
Cassileth, B. R. (1996) · The Oncologist · doi:10.1634/theoncologist.1-3-173 · Cited by 34
Chemotherapy for Advanced Epithelial Ovarian Cancer
Ozols, R. F. (1992) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30316-2 · Cited by 27
Jones, M. A., Siracký, J., Kèlland, L. R., & Harrap, K. R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.5 · Cited by 26
Douple, E. B. (1984) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(84)90003-2 · Cited by 26
Thiery, J. P., Blazsek, I., Legras, S., et al. (1999) · Hepatology · doi:10.1002/hep.510290534 · Cited by 24
Cited by
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Light-Emitting Self-Assembled Materials Based on d8 and d10 Transition Metal Complexes
Yam, V. W.-W., Au, V. K.-M., & Leung, S. Y.-L. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00074 · Cited by 1,661
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Copper in diseases and treatments, and copper‐based anticancer strategies
Tisato, F., Marzano, C., Porchia, M., Pellei, M., & Santini, C. (2010) · Medicinal Research Reviews · doi:10.1002/med.20174 · Cited by 797
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
Metadata
- Authors
- Ho, Y., Au‐Yeung, S. C. F., & To, K. K. W.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2003-05-30
- Volume
- 23
- Issue
- 5
- Pages
- 633-655
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2111570380
- Cited by
- 329
- References
- 91
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.